Spontaneous and therapeutic immune responses in hepatocellular carcinoma: Implications for current and future immunotherapies

Expert Review of Gastroenterology and Hepatology

Volumn 8, Issue 1, 2014, Pages 101-110

  Wirth, Thomas C ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

adaptive immunity; cancer vaccination; hepatocarcinogenesis; hepatocellular carcinoma; immune responses; immunotherapy

Indexed keywords

CANCER VACCINE; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; DENDRITIC CELL VACCINE; PEXASTIMOGENE DEVACIREPVEC; SORAFENIB; TALIMOGENE LAHERPAREPVEC; TICILIMUMAB; TUMOR ANTIGEN;

ADAPTIVE IMMUNITY; ADOPTIVE TRANSFER; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CELLULAR IMMUNITY; CHEMOEMBOLIZATION; DRUG SAFETY; HUMAN; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; NATURAL KILLER T CELL; NONHUMAN; ONCOLYTIC VIROTHERAPY; OUTCOME ASSESSMENT; RADIOFREQUENCY ABLATION; REVIEW; SELECTIVE INTERNAL RADIOTHERAPY; T LYMPHOCYTE ACTIVATION;

ADAPTIVE IMMUNITY; ANTIGENS, NEOPLASM; CARCINOMA, HEPATOCELLULAR; DISEASE PROGRESSION; HUMANS; IMMUNOTHERAPY; LIVER NEOPLASMS; TREATMENT OUTCOME;

EID: 84893152822     PISSN: 17474124     EISSN: 17474132     Source Type: Journal    
DOI: 10.1586/17474124.2014.862497     Document Type: Review

References (143)

1. Fu J, Xu D, Liu Z et al. Increased regulatory T cells correlate with CD8 T-cell impairment and poor survival in hepatocellular carcinoma patients. Gastroenterology 132(7), 2328-2339 (2007
2. Josefowicz SZ, Lu LF, Rudensky AY. Regulatory T cells: Mechanisms of differentiation and function. Ann. Rev. Immunol. 30, 531-564 (2012
3. Ormandy LA, Hillemann T, Wedemeyer H, Manns MP, Greten TF, Korangy F. Increased populations of regulatory T cells in peripheral blood of patients with hepatocellular carcinoma. Cancer Res. 65(6), 2457-2464 (2005
4. Chen KJ, Lin SZ, Zhou L et al. Selective recruitment of regulatory T cell through CCR6-CCL20 in hepatocellular carcinoma fosters tumor progression and predicts poor prognosis. PLoS ONE, 6(9), e24671 (2011
5. Chen KJ, Zhou L, Xie HY, Ahmed TE, Feng XW, Zheng SS. Intratumoral regulatory T cells alone or in combination with cytotoxic T cells predict prognosis of hepatocellular carcinoma after resection. Med. Oncol. 29(3), 1817-1826 (2012
6. Huang Y, Wang FM, Wang T et al Tumor-infiltrating FoxP3+ Tregs and CD8+ T cells affect the prognosis of hepatocellular carcinoma patients. Digestion 86(4), 329-337 (2012
7. Unitt E, Rushbrook SM, Marshall A et al. Compromised lymphocytes infiltrate hepatocellular carcinoma: The role of T-regulatory cells. Hepatology 41(4), 722-730 (2005
8. Pedroza-Gonzalez A, Verhoef C, Ijzermans JN et al. Activated tumor-infiltrating CD4+ regulatory T cells restrain antitumor immunity in patients with primary or metastatic liver cancer. Hepatology 57(1), 183-194 (2013
9. Greten TF, Ormandy LA, Fikuart A et al. Low-dose cyclophosphamide treatment impairs regulatory T cells and unmasks AFP-specific CD4+ T-cell responses in patients with advanced HCC. J. Immunother 33(2), 211-218 (2010
10. Zhang HH, Mei MH, Fei R et al. Regulatory T cell depletion enhances tumor specific CD8 T-cell responses, elicited by tumor antigen NY-ESO-1b in hepatocellular carcinoma patients, in vitro. Inter. J. Oncol. 36(4), 841-848 (2010
11. Haile LA, Greten TF, Korangy F. Immune suppression: The hallmark of myeloid derived suppressor cells. Immunol. Invest. 41(6-7), 581-594 (2012
12. Hoechst B, Ormandy LA, Ballmaier M et al. A new population of myeloid-derived suppressor cells in hepatocellular carcinoma patients induces CD4(+)CD25(+)Foxp3(+) T cells. Gastroenterology 135(1), 234-243 (2008
13. Hoechst B, Voigtlaender T, Ormandy L et al. Myeloid derived suppressor cells inhibit natural killer cells in patients with hepatocellular carcinoma via the NKp30 receptor. Hepatology 50(3), 799-807 (2009
14. Vincent J, Mignot G, Chalmin F et al. 5-Fluorouracil selectively kills tumor-Associated myeloid-derived suppressor cells resulting in enhanced T cell-dependent antitumor immunity. Cancer Res. 70(8), 3052-3061 (2010
15. Le HK, Graham L, Cha E, Morales JK, Manjili MH, Bear HD. Gemcitabine directly inhibits myeloid derived suppressor cells in BALB/c mice bearing 4T1 mammary carcinoma and augments expansion of T cells from tumor-bearing mice. Inter. Immunopharmacol. 9(7-8), 900-909 (2009
16. Zhao Q, Xiao X, Wu Y et al. Interleukin-17-educated monocytes suppress cytotoxic T-cell function through B7-H1 in hepatocellular carcinoma patients. Eur. J. Immunol. 41(8), 2314-2322 (2011
17. Kuang DM, Peng C, Zhao Q, Wu Y, Chen MS, Zheng L. Activated monocytes in peritumoral stroma of hepatocellular carcinoma promote expansion of memory T helper 17 cells. Hepatology 51(1), 154-164 (2010
18. Zhao F, Hoechst B, Gamrekelashvili J et al. Human CCR4+ CCR6+ Th17 cells suppress autologous CD8+ T cell responses. J. Immunol. 188(12), 6055-6062 (2012
19. Liao R, Sun J, Wu H et al. High expression of IL-17 and IL-17RE associate with poor prognosis of hepatocellular carcinoma. J. Exp. Clin. Cancer Res. 32, 3 (2013
20. Ohki S, Shibata M, Gonda K et al. Circulating myeloid-derived suppressor cells are increased and correlate to immune suppression, inflammation and hypoproteinemia in patients with cancer. Oncol. Report. 28(2), 453-458 (2012
21. Zhang JP, Yan J, Xu J et al. Increased intratumoral IL-17-producing cells correlate with poor survival in hepatocellular carcinoma patients. J. Hepatol. 50(5), 980-989 (2009
22. Li YW, Qiu SJ, Fan J et al. Intratumoral neutrophils: A poor prognostic factor for hepatocellular carcinoma following resection. J. Hepatol. 54(3), 497-505 (2011
23. Gomez D, Farid S, Malik HZ et al. Preoperative neutrophil-To-lymphocyte ratio as a prognostic predictor after curative resection for hepatocellular carcinoma. World J. Surg. 32(8), 1757-1762 (2008
24. Liao Y, Wang B, Huang ZL et al. Increased circulating Th17 cells after transarterial chemoembolization correlate with improved survival in stage III hepatocellular carcinoma: A prospective study. PLoS ONE 8(4), e60444 (2013
25. Schurich A, Berg M, Stabenow D et al. Dynamic regulation of CD8 T cell tolerance induction by liver sinusoidal endothelial cells. J. Immunol. 184(8), 4107-4114 (2010
26. Bottcher JP, Schanz O, Wohlleber D et al. Liver-primed memory T cells generated under noninflammatory conditions provide anti-infectious immunity. Cell Rep. 3(3), 779-795 (2013
27. Zeng Z, Yao W, Xu X et al. Hepatocellular carcinoma cells deteriorate the biophysical properties of dendritic cells. Cell Biochem. Biophy. 55(1), 33-43 (2009
28. Xia Y, Chen R, Ye SL, Sun R, Chen J, Zhao Y. Inhibition of T-cell responses by intratumoral hepatic stellate cells contribute to migration and invasion of hepatocellular carcinoma. Clin. Exp. Metastasis 28(7), 661-674 (2011
29. Zhao W, Su W, Kuang P et al. The role of hepatic stellate cells in the regulation of T-cell function and the promotion of hepatocellular carcinoma. Int. J. Oncol. 41(2), 457-464 (2012
30. Mizukoshi E, Nakamoto Y, Arai K et al. Comparative analysis of various tumor-Associated antigen-specific t-cell responses in patients with hepatocellular carcinoma. Hepatology 53(4), 1206-1216 (2011
31. Mizukoshi E, Nakamoto Y, Marukawa Y et al. Cytotoxic T cell responses to human telomerase reverse transcriptase in patients with hepatocellular carcinoma. Hepatology 43(6), 1284-1294 (2006
32. Thimme R, Neagu M, Boettler T et al. Comprehensive analysis of the alpha-fetoprotein-specific CD8+ T cell responses in patients with hepatocellular carcinoma. Hepatology 48(6), 1821-1833 (2008
33. Behboudi S, Boswell S, Williams R. Cell-mediated immune responses to alpha-fetoprotein and other antigens in hepatocellular carcinoma. Liver Int. 30(4), 521-526 (2010
34. Butterfield LH, Ribas A, Potter DM, Economou JS. Spontaneous and vaccine induced AFP-specific T cell phenotypes in subjects with AFP-positive hepatocellular cancer. Cancer Immunol. Immunother. 56(12), 1931-1943 (2007
35. Mizukoshi E, Nakamoto Y, Tsuji H, Yamashita T, Kaneko S. Identification of alpha-fetoprotein-derived peptides recognized by cytotoxic T lymphocytes in HLA-A24+ patients with hepatocellular carcinoma. Int. J. Cancer 118(5), 1194-1204 (2006
36. Bei R, Budillon A, Reale MG et al. Cryptic epitopes on alpha-fetoprotein induce spontaneous immune responses in hepatocellular carcinoma, liver cirrhosis, and chronic hepatitis patients. Cancer Res. 59(21), 5471-5474 (1999
37. Bei R, Mizejewski GJ. Alpha fetoprotein is more than a hepatocellular cancer biomarker: From spontaneous immune response in cancer patients to the development of an AFP-based cancer vaccine. Curr. Mol. Med. 11(7), 564-581 (2011
38. Evdokimova VN, Liu Y, Potter DM, Butterfield LH. AFP-specific CD4+ helper T-cell responses in healthy donors and HCC patients. J. Immunother. 30(4), 425-437 (2007
39. Witkowski M, Spangenberg HC, Neumann-Haefelin C et al. Lack of ex vivo peripheral and intrahepatic alpha-fetoprotein-specific CD4+ responses in hepatocellular carcinoma. Int. J. Cancer 129(9), 2171-2182 (2011
40. Motomura Y, Ikuta Y, Kuronuma T et al. HLA-A2 and-A24-restricted glypican-3-derived peptide vaccine induces specific CTLs: Preclinical study using mice. Int. J. Oncol. 32(5), 985-990 (2008
41. Shang XY, Chen HS, Zhang HG et al. The spontaneous CD8+ T-cell response to HLA-A2-restricted NY-ESO-1b peptide in hepatocellular carcinoma patients. Clin. Cancer Res. 10(20), 6946-6955 (2004
42. Korangy F, Ormandy LA, Bleck JS et al. Spontaneous tumor-specific humoral and cellular immune responses to NY-ESO-1 in hepatocellular carcinoma. Clin. Cancer Res. 10(13), 4332-4341 (2004
43. Zhang HG, Chen HS, Peng JR. et al. Specific CD8(+)T cell responses to HLA-A2 restricted MAGE-A3 p271-279 peptide in hepatocellular carcinoma patients without vaccination. Cancer Immunol. Immunother. 56(12), 1945-1954 (2007
44. Bricard G, Bouzourene H, Martinet O et al. Naturally acquired MAGE-A10-And SSX-2-specific CD8+ T cell responses in patients with hepatocellular carcinoma. J. Immunol. 174(3), 1709-1716 (2005
45. Song MH, Choi KU, Shin DH, Lee CH, Lee SY. Identification of the cancer/testis antigens AKAP3 and CTp11 by SEREX in hepatocellular carcinoma. Oncol. Rep. 28(5), 1792-1798 (2012
46. Shen H, Shao HW, Chen XH et al. Identification of a novel HLA-A2-restricted mutated Survivin epitope and induction of specific anti-HCC CTLs that could effectively cross-recognize wild-Type Survivin antigen. Cancer Immunol. Immunother. 62(2), 393-403 (2013
47. Mizukoshi E, Fushimi K, Arai K, Yamashita T, Honda M, Kaneko S. Expression of chondroitin-glucuronate C5-epimerase and cellular immune responses in patients with hepatocellular carcinoma. Liver Int. 32(10), 1516-1526 (2012
48. Dong XY, Yang XA, Wang YD, Chen WF. Zinc-finger protein ZNF165 is a novel cancer-Testis antigen capable of eliciting antibody response in hepatocellular carcinoma patients. Br. J. Cancer 91(8), 1566-1570 (2004
49. Shimoda M, Tomimaru Y, Charpentier KP, Safran H, Carlson RI, Wands J. Tumor progression-related transmembrane protein aspartate-beta-hydroxylase is a target for immunotherapy of hepatocellular carcinoma. J. Hepatol. 56(5), 1129-1135 (2012
50. Stauffer JK, Scarzello AJ, Jiang Q, Wiltrout RH. Chronic inflammation, immune escape, and oncogenesis in the liver: A unique neighborhood for novel intersections. Hepatology 56(4), 1567-1574 (2012
51. He G, Karin M. NF-kappaB and STAT3-key players in liver inflammation and cancer. Cell Res. 21(1), 159-168 (2011
52. Wong VW, Yu J, Cheng AS et al. High serum interleukin-6 level predicts future hepatocellular carcinoma development in patients with chronic hepatitis B. Int. J. Cancer 124(12), 2766-2770 (2009
53. Bettermann K, Vucur M, Haybaeck J et al. TAK1 suppresses a NEMO-dependent but NF-kappaB-independent pathway to liver cancer. Cancer Cell 17(5), 481-496 (2010
54. Sakurai T, He G, Matsuzawa A et al. Hepatocyte necrosis induced by oxidative stress and IL-1 alpha release mediate carcinogen-induced compensatory proliferation and liver tumorigenesis. Cancer Cell 14(2), 156-165 (2008
55. Schneider C, Teufel A, Yevsa T et al. Adaptive immunity suppresses formation and progression of diethylnitrosamine-induced liver cancer. Gut 61(12), 1733-1743 (2012
56. Nakamoto Y, Guidotti LG, Kuhlen CV, Fowler P, Chisari FV. Immune pathogenesis of hepatocellular carcinoma. J. Exp. Med. 188(2), 341-350 (1998
57. Haybaeck J, Zeller N, Wolf MJ et al. A lymphotoxin-driven pathway to hepatocellular carcinoma. Cancer Cell 16(4), 295-308 (2009
58. Unitt E, Marshall A, Gelson W et al. Tumour lymphocytic infiltrate and recurrence of hepatocellular carcinoma following liver transplantation. J. Hepatol. 45(2), 246-253 (2006
59. Flecken T, Schmidt N, Hild S et al. Immunodominance and functional alterations of tumor-Associated antigenspecific CD8 T-cell responses in hepatocellular carcinoma. Hepatology doi:10.1002/hep.26731 (2013) (Epub ahead of print
60. Gao B, Radaeva S, Park O. Liver natural killer and natural killer T cells: Immunobiology and emerging roles in liver diseases. J. Leuk. Biol. 86(3), 513-528 (2009
61. Subleski JJ, Jiang Q, Weiss JM, Wiltrout RH. The split personality of NKT cells in malignancy, autoimmune and allergic disorders. Immunotherapy 3(10), 1167-1184 (2011
62. Doi H, Iyer TK, Carpenter E et al. Dysfunctional B-cell activation in cirrhosis resulting from hepatitis C infection associated with disappearance of CD27-positive B-cell population. Hepatology 55(3), 709-719 (2012
63. de Visser KE, Korets LV, Coussens LM. De novo carcinogenesis promoted by chronic inflammation is B lymphocyte dependent. Cancer Cell 7(5), 411-423 (2005
64. Kobayashi N, Hiraoka N, Yamagami W et al. FOXP3+ regulatory T cells affect the development and progression of hepatocarcinogenesis. Clin. Cancer Res. 13(3), 902-911 (2007
65. Hu CE, Gan J, Zhang RD, Cheng YR, Huang GJ. Up-regulated myeloid-derived suppressor cell contributes to hepatocellular carcinoma development by impairing dendritic cell function. Scand. J. Gastroenterol. 46(2), 156-164 (2011
66. Kang TW, Yevsa T, Woller N et al. Senescence surveillance of pre-malignant hepatocytes limits liver cancer development. Nature 479(7374), 547-551 (2011
67. Vesely MD, Kershaw MH, Schreiber RD, Smyth MJ. Natural innate and adaptive immunity to cancer. Ann. Rev. Immunol. 29, 235-271 (2011
68. Lin H, Yan J, Wang Z et al. Loss of immunity-supported senescence enhances susceptibility to hepatocellular carcinogenesis and progression in Toll-like receptor 2-deficient mice. Hepatology 57(1), 171-182 (2013
69. Kaposi-Novak P, Libbrecht L, Woo HG et al. Central role of c-Myc during malignant conversion in human hepatocarcinogenesis. Cancer Res. 69(7), 2775-2782 (2009
70. Wu CH, van Riggelen J, Yetil A, Fan AC, Bachireddy P, Felsher DW. Cellular senescence is an important mechanism of tumor regression upon c-Myc inactivation. Proc. Natl Acad. Sci. USA 104(32), 13028-13033 (2007
71. Xue W, Zender L, Miething C et al. Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas. Nature 445(7128), 656-660 (2007
72. Braumuller H, Wieder T, Brenner E et al. T-helper-1-cell cytokines drive cancer into senescence. Nature 494(7437), 361-365 (2013
73. Kumar V, Kato N, Urabe Y et al. Genome-wide association study identifies a susceptibility locus for HCV-induced hepatocellular carcinoma. Nat. Genet. 43(5), 455-458 (2011
74. Butterfield LH, Koh A, Meng W et al. Generation of human T-cell responses to an HLA-A2.1-restricted peptide epitope derived from alpha-fetoprotein. Cancer Res. 59(13), 3134-3142 (1999
75. Gehring AJ, Ho ZZ, Tan AT et al. Profile of tumor antigen-specific CD8 T cells in patients with hepatitis B virus-related hepatocellular carcinoma. Gastroenterology 137(2), 682-690 (2009
76. Huz JI, Melis M, Sarpel U. Spontaneous regression of hepatocellular carcinoma is most often associated with tumour hypoxia or a systemic inflammatory response. HPB (Oxford) 14(8), 500-505 (2012
77. Storey RE, Huerta AL, Khan A, Laber DA. Spontaneous complete regression of hepatocellular carcinoma. Med. Oncol. 28(4), 948-950 (2011
78. Blondon H, Fritsch L, Cherqui D. Two cases of spontaneous regression of multicentric hepatocellular carcinoma after intraperitoneal rupture: Possible role of immune mechanisms. Eur. J. Gastroenterol. Hepatol. 16(12), 1355-1359 (2004
79. Zerbini A, Pilli M, Soliani P et al. Ex vivo characterization of tumor-derived melanoma antigen encoding gene-specific CD8+cells in patients with hepatocellular carcinoma. J. Hepatol. 40(1), 102-109 (2004
80. Harimoto N, Shirabe K, Kajiyama K et al. Spontaneous regression of multiple pulmonary recurrences of hepatocellular carcinoma after hepatectomy: Report of a case. Surg. Today 42(5), 475-478 (2012
81. Mizukoshi E, Yamashita T, Arai K et al. Enhancement of tumor-Associated antigenspecific T cell responses by radiofrequency ablation of hepatocellular carcinoma. Hepatology 57(4), 1448-1457 (2013
82. Xia JZ, Xie FL, Ran LF, Xie XP, Fan YM, Wu F. High-intensity focused ultrasound tumor ablation activates autologous tumor-specific cytotoxic T lymphocytes. Ultrasound Med. Biol. 38(8), 1363-1371 (2012
83. Zerbini A, Pilli M, Fagnoni F et al. Increased immunostimulatory activity conferred to antigen-presenting cells by exposure to antigen extract from hepatocellular carcinoma after radiofrequency thermal ablation. J. Immunother. 31(3), 271-282 (2008
84. Zerbini A, Pilli M, Penna A et al. Radiofrequency thermal ablation of hepatocellular carcinoma liver nodules can activate and enhance tumor-specific T-cell responses. Cancer Res. 66(2), 1139-1146 (2006
85. Ali MY, Grimm CF, Ritter M et al. Activation of dendritic cells by local ablation of hepatocellular carcinoma. J. Hepatol. 43(5), 817-822 (2005
86. Nobuoka D, Motomura Y, Shirakawa H et al. Radiofrequency ablation for hepatocellular carcinoma induces glypican-3 peptide-specific cytotoxic T lymphocytes. Int. J. Oncol. 40(1), 63-70 (2012
87. Ayaru L, Pereira SP, Alisa A et al. Unmasking of alpha-fetoprotein- specific CD4(+) T cell responses in hepatocellular carcinoma patients undergoing embolization. J. Immunol. 178(3), 1914-1922 (2007
88. Edwards JP, Emens LA. The multikinase inhibitor sorafenib reverses the suppression of IL-12 and enhancement of IL-10 by PGE(2) in murine macrophages. Int. Immunopharmacol. 10(10), 1220-1228 (2010
89. Chen ML, Yan BS, Lu WC et al. Sorafenib relieves cell-intrinsic and cell-extrinsic inhibitions of effector T cells in tumor microenvironment to augment antitumor immunity. Int. J. Cancer doi:10.1002/ ijc.28362 (2013) (Epub ahead of print
90. Sprinzl MF, Reisinger F, Puschnik A et al. Sorafenib perpetuates cellular anticancer effector functions by modulating the crosstalk between macrophages and natural killer cells. Hepatology 57(6), 2358-2368 (2013
91. Wang Q, Yu T, Yuan Y et al. Sorafenib reduces hepatic infiltrated regulatory T cells in hepatocellular carcinoma patients by suppressing TGF-beta signal. J. Surg. Oncol. 107(4), 422-427 (2013
92. Cao M, Xu Y, Youn JI et al. Kinase inhibitor Sorafenib modulates immunosuppressive cell populations in a murine liver cancer model. Lab. Invest. 91(4), 598-608 (2011
93. Cabrera R, Ararat M, Xu Y et al. Immune modulation of effector CD4+ and regulatory T cell function by sorafenib in patients with hepatocellular carcinoma. Cancer Immunol. Immunother. 62(4), 737-746 (2013
94. Nagai H, Mukozu T, Matsui D et al. Sorafenib prevents escape from host immunity in liver cirrhosis patients with advanced hepatocellular carcinoma. Clin. Dev. Immunol. 2012, 607851 (2012
95. Hipp MM, Hilf N, Walter S et al. Sorafenib, but not sunitinib, affects function of dendritic cells and induction of primary immune responses. Blood 111(12), 5610-5620 (2008
96. Weng DS, Zhou J, Zhou QM et al. Minimally invasive treatment combined with cytokine-induced killer cells therapy lower the short-Term recurrence rates of hepatocellular carcinomas. J. Immunother. 31(1), 63-71 (2008
97. Takayama T, Sekine T, Makuuchi M et al. Adoptive immunotherapy to lower postsurgical recurrence rates of hepatocellular carcinoma: A randomised trial. Lancet 356(9232), 802-807 (2000
98. Kuang M, Peng BG, Lu MD et al. Phase II randomized trial of autologous formalin-fixed tumor vaccine for postsurgical recurrence of hepatocellular carcinoma. Clin. Cancer Res. 10(5), 1574-1579 (2004
99. Pan K, Li YQ, Wang W et al. The efficacy of cytokine-induced killer cell infusion as an adjuvant therapy for postoperative hepatocellular carcinoma patients. Ann. Surg. Oncol. (2013) (Epub ahead of print
100. Zhong JH, Li H, Li LQ et al. Adjuvant therapy options following curative treatment of hepatocellular carcinoma: A systematic review of randomized trials. Eur. J. Surg. Oncol. 38(4), 286-295 (2012
101. Inui T, Ohno T. Autologous formalin-fixed tumor vaccine suppressed re-recurrence of HCV-related hepatocellular carcinoma following 29 unsuccessful treatments with extensive conventional therapy: A case report. World J. Surg. Oncol. 10, 144 (2012
102. Sun K, Wang L, Zhang Y. Dendritic cell as therapeutic vaccines against tumors and its role in therapy for hepatocellular carcinoma. Cell. Mol. Immunol. 3(3), 197-203 (2006
103. El Ansary M, Mogawer S, Elhamid SA et al. Immunotherapy by autologous dendritic cell vaccine in patients with advanced HCC. J. Cancer Res. Clin. Oncol. 139(1), 39-48 (2013
104. Palmer DH, Midgley RS, Mirza N et al. A phase II study of adoptive immunotherapy using dendritic cells pulsed with tumor lysate in patients with hepatocellular carcinoma. Hepatology 49(1), 124-132 (2009
105. Lee WC, Wang HC, Hung CF, Huang PF, Lia CR, Chen MF. Vaccination of advanced hepatocellular carcinoma patients with tumor lysate-pulsed dendritic cells: A clinical trial. J. Immunother. 28(5), 496-504 (2005
106. Ladhams A, Schmidt C, Sing G et al. Treatment of non-resectable hepatocellular carcinoma with autologous tumor-pulsed dendritic cells. J. Gastroenterol. Hepatol. 17(8), 889-896 (2002
107. Nakamoto Y, Mizukoshi E, Tsuji H et al. Combined therapy of transcatheter hepatic arterial embolization with intratumoral dendritic cell infusion for hepatocellular carcinoma: Clinical safety. Clin. Exp. Immunol. 147(2), 296-305 (2007
108. Mizukoshi E, Nakamoto Y, Arai K et al. Enhancement of tumor-specific T-cell responses by transcatheter arterial embolization with dendritic cell infusion for hepatocellular carcinoma. Int. J. Cancer 126(9), 2164-2174 (2010
109. Zhang HM, Zhang LW, Liu WC, Cheng J, Si XM, Ren J. Comparative analysis of DC fused with tumor cells or transfected with tumor total RNA as potential cancer vaccines against hepatocellular carcinoma. Cytotherapy 8(6), 580-588 (2006
110. Zhang H, Zheng SS, Jiang GP, Wu LH, Zhu F, Yang ZL. Antitumor effect of immunization with fusion of dendritic cells and hepatocellular carcinoma cells in mice. Hepatobiliary Pancreat. Dis. Int. 3(2), 235-240 (2004
111. Vollmer CM Jr, Eilber FC, Butterfield LH et al. Alpha-fetoprotein- specific genetic immunotherapy for hepatocellular carcinoma. Cancer Res. 59(13), 3064-3067 (1999
112. Zhang W, Liu J, Wu Y et al. Immunotherapy of hepatocellular carcinoma with a vaccine based on xenogeneic homologous alpha fetoprotein in mice. Biochem. Biophys. Res. Commun. 376(1), 10-14 (2008
113. Sawada Y, Yoshikawa T, Nobuoka D et al. Phase I trial of a glypican-3-derived peptide vaccine for advanced hepatocellular carcinoma: Immunologic evidence and potential for improving overall survival. Clin. Cancer Res. 18(13), 3686-3696 (2012
114. Zhu AX, Gold PJ, El-Khoueiry AB et al. First-in-man phase I study of GC33, a novel recombinant humanized antibody against glypican-3, in patients with advanced hepatocellular carcinoma. Clin. Cancer Res. 19(4), 920-928 (2013
115. Qiu Y, Xu MB, Yun MM et al. Hepatocellular carcinoma-specific immunotherapy with synthesized alpha1,3-galactosyl epitope-pulsed dendritic cells and cytokine-induced killer cells. World J. Gastroenterol. 17(48), 5260-5266 (2011
116. Greten TF, Forner A, Korangy F et al. A phase II open label trial evaluating safety and efficacy of a telomerase peptide vaccination in patients with advanced hepatocellular carcinoma. BMC Cancer 10, 209 (2010
117. Zhang XM, Zhang YF, Huang Y et al. The anti-Tumor immune response induced by a combination of MAGE-3/MAGE-n-derived peptides. Oncol. Rep. 20(1), 245-252 (2008
118. Wang XH, Qin Y, Hu MH, Xie Y. Dendritic cells pulsed with gp96-peptide complexes derived from human hepatocellular carcinoma (HCC) induce specific cytotoxic T lymphocytes. Cancer Immunol. Immunother. 54(10), 971-980 (2005
119. Ren W, Strube R, Zhang X, Chen SY, Huang XF. Potent tumor-specific immunity induced by an in vivo heat shock protein-suicide gene-based tumor vaccine. Cancer Res. 64(18), 6645-6651 (2004
120. Hodi FS, O'Day SJ, McDermott DF et al. Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 363(8), 711-723 (2010
121. Shi F, Shi M, Zeng Z et al. PD-1 and PD-L1 upregulation promotes CD8(+) T-cell apoptosis and postoperative recurrence in hepatocellular carcinoma patients. Int. J. Cancer 128(4), 887-896 (2011
122. Hsu PN, Yang TC, Kao JT et al. Increased PD-1 and decreased CD28 expression in chronic hepatitis B patients with advanced hepatocellular carcinoma. Liver Int. 30(9), 1379-1386 (2010
123. Wang BJ, Bao JJ, Wang JZ et al. Immunostaining of PD-1/PD-Ls in liver tissues of patients with hepatitis and hepatocellular carcinoma. World J. Gastroenterol. 17(28), 3322-3329 (2011
124. Kalathil S, Lugade AA, Miller A, Iyer R, Thanavala Y. Higher frequencies of GARP (+)CTLA-4(+)Foxp3(+) T regulatory cells and myeloid-derived suppressor cells in hepatocellular carcinoma patients are associated with impaired T-cell functionality. Cancer Res. 73(8), 2435-2444 (2013
125. Hu L, Liu J, Chen X et al. CTLA-4 gene polymorphism +49 A/G contributes to genetic susceptibility to two infection-related cancers-hepatocellular carcinoma and cervical cancer. Hum. Immunol. 71(9), 888-891 (2010
126. Willimsky G, Schmidt K, Loddenkemper C, Gellermann J, Blankenstein T. Virusinduced hepatocellular carcinomas cause antigen-specific local tolerance. J. Clin. Invest. 123(3), 1032-1043 (2013
127. Sangro B, Gomez-Martin C, de la Mata M et al. A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C. J. Hepatol. 59(1), 81-88 (2013
128. Li FJ, Zhang Y, Jin GX, Yao L, Wu DQ. Expression of LAG-3 is coincident with the impaired effector function of HBV-specific CD8(+) T cell in HCC patients. Immunol. Lett. 150(1-2), 116-122 (2013
129. Li H, Wu K, Tao K et al. Tim-3/galectin-9 signaling pathway mediates T-cell dysfunction and predicts poor prognosis in patients with hepatitis B virus-Associated hepatocellular carcinoma. Hepatology 56(4), 1342-1351 (2012
130. Senzer NN, Kaufman HL, Amatruda T et al. Phase II clinical trial of a granulocyte-macrophage colony-stimulating factor-encoding, second-generation oncolytic herpesvirus in patients with unresectable metastatic melanoma. J. Clin. Oncol. 27(34), 5763-5771 (2009
131. Heo J, Reid T, Ruo L et al. Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancer. Nat. Med. 19(3), 329-336 (2013
132. Butterfield LH, Ribas A, Dissette VB et al. A phase I/II trial testing immunization of hepatocellular carcinoma patients with dendritic cells pulsed with four alpha-fetoprotein peptides. Clin. Cancer Res. 12(9), 2817-2825 (2006
133. Butterfield LH, Meng WS, Koh A et al. T cell responses to HLA-A. 0201-restricted peptides derived from human alpha fetoprotein. J. Immunol. 166(8), 5300-5308 (2001
134. Han Y, Chen Z, Yang Y et al. Human CD14 CTLA-4 regulatory dendritic cells suppress T cell response via CTLA-4-dependent IL-10 and IDO production in hepatocellular carcinoma. Hepatology doi:10.1002/hep.26694 (2013) (Epub ahead of print
135. Gao Q, Wang XY, Qiu SJ et al. Overexpression of PD-L1 significantly associates with tumor aggressiveness and postoperative recurrence in human hepatocellular carcinoma. Clin. Cancer Res. 15(3), 971-979 (2009
136. Yan J, Zhang Y, Zhang JP, Liang J, Li L, Zheng L. Tim-3 expression defines regulatory T cells in human tumors. PLoS ONE 8(3), e58006 (2013
137. Li Z, Liu Z, Zhang G et al. TIM3 gene polymorphisms in patients with chronic hepatitis B virus infection: Impact on disease susceptibility and hepatocellular carcinoma traits. Tissue Antigens 80(2), 151-157 (2012
138. Tatsumi T, Takehara T, Katayama K et al. Expression of costimulatory molecules B7-1 (CD80) and B7-2 (CD86) on human hepatocellular carcinoma. Hepatology 25(5), 1108-1114 (1997
139. Maki A, Matsuda M, Asakawa M, Kono H, Fujii H, Matsumoto Y. Decreased expression of CD28 coincides with the down-modulation of CD3zeta and augmentation of caspase-3 activity in T cells from hepatocellular carcinoma-bearing patients and hepatitis C virus-infected patients. J. Gastroenterol. Hepatol. 19(12), 1348-1356 (2004
140. Gonzalez-Carmona MA, Lukacs-Kornek V, Timmerman A et al. CD40ligand-expressing dendritic cells induce regression of hepatocellular carcinoma by activating innate and acquired immunity in vivo. Hepatology 48(1), 157-168 (2008
141. Iida T, Shiba H, Misawa T, Ohashi T, Eto Y, Yanaga K. Adenovirus-mediated CD40L gene therapy induced both humoral and cellular immunity against rat model of hepatocellular carcinoma. Cancer Sci. 99(10), 2097-2103 (2008
142. Morales-Kastresana A, Sanmamed MF, Rodriguez I et al. Combined immunostimulatory monoclonal antibodies extend survival in an aggressive transgenic hepatocellular carcinoma mouse model. Clin. Cancer Res. (2013) (Epub ahead of print
143. Wan YL, Zheng SS, Zhao ZC, Li MW, Jia CK, Zhang H. Expression of co-stimulator 4-1BB molecule in hepatocellular carcinoma and adjacent non-Tumor liver tissue, and its possible role in tumor immunity. World J. Gastroenterol. 10(2), 195-99 (2004)